Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $11.6M | $97.0K | $59.0K | $73.0K | $75.0K | $0.00 | — |
| Revenue growth | — | -99.2% | -39.2% | 23.7% | 2.7% | -100.0% | — |
| Operating income | $2.58M | -$8.28M | -$13.6M | -$17.9M | -$19.1M | -$22.5M | -$41.8M |
| Operating margin | 22.4% | -8537.1% | -23044.1% | -24457.5% | -25441.3% | — | — |
| Net income | $2.61M | -$8.27M | -$13.9M | -$18.2M | -$19.6M | -$21.8M | -$37.9M |
| Net margin | 22.6% | -8529.9% | -23528.8% | -24942.5% | -26082.7% | — | — |
| EPS (diluted) | $3.05 | -$8.10 | -$3.23 | -$37.88 | -$14.12 | -$1.22 | -$1.05 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.79M | -$7.54M | -$12.8M | -$15.9M | -$18.0M | -$19.4M | -$23.6M |
| Capital expenditures | $404K | $95.0K | $221K | $13.0K | $1.00K | $179K | $18.0K |
| Free cash flow | $4.39M | -$7.63M | -$13.1M | -$15.9M | -$18.0M | -$19.6M | -$23.6M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15.7M | $9.80M | $19.8M | $4.06M | $2.48M | $50.9M | $97.7M |
| Total assets | $19.2M | $11.6M | $21.4M | $5.97M | $4.46M | $52.2M | $99.6M |
| Total liabilities | $2.64M | $1.35M | $1.37M | $3.09M | $4.26M | $4.96M | $2.30M |
| Shareholders' equity | $16.6M | $10.2M | $20.0M | $2.88M | $202K | $47.2M | $97.3M |
| Retained earnings | -$109M | -$117M | -$130M | -$148M | -$168M | -$190M | -$228M |
| Shares (wtd avg diluted) | 857K | 1.11M | 4.30M | 481K | 1.39M | 18.4M | 36.2M |
Every figure is extracted from Benitec Biopharma Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.